CompletedPhase 1

Effect of Relamorelin on Satiation, Gastric Volume, Gastric Accommodation and Distal Gastric Function in Healthy Volunteers

United States16 participantsStarted 2015-06

Plain-language summary

The purpose of this study is to evaluate the effects of relamorelin (RM-131) on gastric volume, motor and sensory effects in healthy patients.

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. Able to provide written informed consent prior to any study procedures, and be willing and able to comply with study procedures
✓. No medical problems or chronic diseases, specifically, no type 2 diabetes mellitus
✓. Body mass index of 18-35 kg/m²
✓. Female subjects must have negative urine pregnancy tests and must not be lactating prior to receiving study medication and radiation exposure. For females able to bear children, a hormonal (i.e., oral, implantable, or injectable) and single-barrier method, or a double-barrier method of birth control must be used throughout the study. Female subjects unable to bear children must have this documented in the medical record (i.e., tubal ligation, hysterectomy, or post-menopausal \[defined as a minimum of one year since the last menstrual period\]).

✕. Unable or unwilling to provide informed consent or to comply with study procedures
✕. Diagnosis of gastrointestinal diseases
✕. Structural or metabolic diseases that affect the GI system
✕. Unable to avoid the following over- the- counter medications 48 hours prior to the baseline period and throughout the study:
✕. Medications that alter GI transit including laxatives, magnesium and aluminum containing antacids, prokinetics, erythromycin,
✕. Analgesic drugs including NSAIDs and COX-2 inhibitors NOTE: stable doses of thyroid replacement, estrogen replacement, low-dose aspirin for cardioprotection, and birth control (but with adequate backup contraception as drug-interactions with birth control have not been conducted) are permissible.
✕. History of recent surgery (within 60 days of screening)
✕. Acute or chronic illness or history of illness, which in the opinion of the Investigator, could pose a threat or harm to the subject or obscure interpretation of laboratory test results or interpretation of study data such as frequent angina, Class III or IV congestive heart failure, moderate impairment of renal or hepatic function, poorly controlled diabetes, etc.

Gastric volume measured by single photon emission computed tomography (SPECT)

Timeframe: Measured during the 1 hour study procedure

Satiety measured by the Hunger/Satiety questionnaire

Timeframe: Measured during a 1 hour study procedure

Gastric motility measured by gastroduodenal manometry

Timeframe: Measured during the 4 hour study procedure

NCT IDNCT02466711

SponsorMotus Therapeutics, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2015-08

Who can participate